Clinical Trial Detail

NCT ID NCT02660034
Title The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors BeiGene
Indications

stomach cancer

ovary epithelial cancer

pancreatic adenocarcinoma

Advanced Solid Tumor

fallopian tube cancer

prostate cancer

ureter cancer

peritoneum cancer

lung small cell carcinoma

renal pelvis carcinoma

invasive bladder transitional cell carcinoma

gastroesophageal junction adenocarcinoma

transitional cell carcinoma

triple-receptor negative breast cancer

Therapies

Pamiparib + Tislelizumab

Age Groups: adult senior

Additional content available in CKB BOOST